Quest Diagnostics, Inc’s recently made public that its SVP for Diagnostic Services Plewman Patrick unloaded Company’s shares for reported $0.97 million on Aug 06 ’25. In the deal valued at $175.00 per share,5,535 shares were sold. As a result of this transaction, Plewman Patrick now holds 19,219 shares worth roughly $3.4 million.
Then, Plewman Patrick bought 5,535 shares, generating $968,625 in total proceeds.
Before that, KUPPUSAMY KARTHIK sold 8,269 shares. Quest Diagnostics, Inc shares valued at $1,384,231 were divested by the SVP, Clinical Solutions at a price of $167.40 per share. As a result of the transaction, KUPPUSAMY KARTHIK now holds 10,660 shares, worth roughly $1.89 million.
Redburn Atlantic initiated its Quest Diagnostics, Inc [DGX] rating to a Buy in a research note published on April 02, 2025; the price target was $195. A number of analysts have revised their coverage, including Citigroup’s analysts, who decreased its forecast for the stock in early March from “a Buy” to “a Neutral”. Leerink Partners also remained covering DGX and has increased its forecast on January 06, 2025 with a “an Outperform” recommendation from previously “Market perform” rating. Morgan Stanley revised its rating on December 17, 2024. It rated DGX as “an Overweight” which previously was an “an Equal-weight”.
Price Performance Review of DGX
On Friday, Quest Diagnostics, Inc [NYSE:DGX] saw its stock jump 1.54% to $176.96. Over the last five days, the stock has gained 3.58%. Quest Diagnostics, Inc shares have risen nearly 20.47% since the year began. Nevertheless, the stocks have risen 17.30% over the past one year.
How much short interest is there in Quest Diagnostics, Inc?
A steep rise in short interest was recorded in Quest Diagnostics, Inc stocks on 2025-07-15, growing by 0.94 million shares to a total of 4.58 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 3.64 million shares. There was a rise of 20.45%, which implies that there is a positive sentiment for the stock.
